Our 5 Year Goals / Building Blocks of Growth
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
Our StrategyIn June, 2012, Cubist announced the Company’s five-year strategic aspirations — Building Blocks of Growth. The Company’s five-year roadmap, including goals for top- and bottom-line growth, future pipeline developments, and cultural elements will position Cubist to deliver long-term, sustainable growth. Cubist has established itself as a global leader in the acute care/hospital environment. Our Building Blocks of Growth will help the company build on this momentum as we look to deliver important new medicines for patients and drive long-term value for our customers and shareholders. The Building Blocks of Growth reflects what sets Cubist apart and will help us sharpen our organizational focus through 2017.
Acute care is the space where we work and invest. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides, and ENTEREG® (alvimopan), the first and only FDA-approved therapy to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis. Cubist also markets DIFICID® (fidaxomicin) in the U.S. and Canada, for the treatment of Clostridium difficile-associated diarrhea (CDAD).
Cubist is headquartered in Lexington, MA and employs approximately 900 people. 2013 Total net revenues grew 14% to $1.1 billion compared to $926.4 million in 2012.
Cubist's clinical product pipeline includes a novel, antipseudomonal cephalosporin and a well-established β-lactamase inhibitor in development to address certain serious infections caused by Gram-negative organisms. Cubist recently completed pivotal Phase 3 clinical trials of this antibiotic candidate in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), and expects to initiate a pivotal Phase 3 trial in Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) during the first half of 2014.
Global regulatory reviews and submissions are in process following completion of a Phase 3 program of a novel oxazolidinone in development for the potential treatment of certain Gram-positive infections, including MRSA.
Additionally, Cubist is conducting a Phase 3 program for the potential treatment of diarrhea caused by Clostridium difficile (C. difficile), as well as a long-term safety trial for chronic opioid induced constipation (OIC) in patients with chronic non-cancer pain.
Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and agents to treat acute pain.
Founded in 1992, Cubist has maintained its focus on becoming a leader in the discovery, development and commercialization of novel acute care therapies for use in hospitals and other acute care environments.
Is focused on becoming a leader in the discovery, development and commercialization of novel acute care therapies for use in hospitals and other acute care environments.
Cubist completed its initial public offering (IPO) in 1996, and its shares are listed on NASDAQ (ticker symbol: CBST). In 1997, at a time when most pharmaceutical companies had abandoned discovery and development of antibiotics, Cubist in-licensed daptomycin, a first-in-class cyclic lipopeptide antibiotic drug candidate, originally discovered by scientists at Eli Lilly, which had discontinued its work on daptomycin as a drug candidate. Based on a breakthrough by Cubist scientists, Cubist resumed human trials with daptomycin in I.V. form, and the drug was approved by the FDA in 2003 as CUBICIN for the treatment of complicated skin and skin structure infections caused by certain Gram-positive organisms. In 2006, the FDA approved an expanded U.S. label for CUBICIN for the treatment of S. aureus bloodstream infections (bacteremia), including right-sided infective endocarditis caused by MRSA and MSSA. The approval was based on results of the company's landmark Phase 3 trial studying the treatment of S. aureus bloodstream infections, including infective endocarditis. Today, we partner with other pharmaceutical companies to make CUBICIN available outside the United States in more than 70 countries, and the list continues to grow.
In September 2013, through its acquisition of Trius Therapeutics, Cubist acquired rights to the late-stage antibiotic candidate, tedizolid phosphate a second generation oxazolidinone in development for the treatment of certain Gram-positive infections, including MRSA. In October 2013, through its acquisition of Optimer Pharmaceuticals, Cubist acquired rights to DIFICID® (fidamoxicin).Click here for more information on Cubist's Pipeline.